Foamix Pharmaceuticals Ltd, a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced the pricing of an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $9.50 per share. Of the ordinary shares, 5,700,000 shares will be sold by Foamix and 300,000 shares will be sold by certain selling shareholders. In addition, Foamix has granted the underwriters a 30-day option to purchase up to 900,000 additional ordinary shares . The offering is expected to close on Friday, September 30, 2016, subject to customary closing conditions.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological conditions.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.